Table of Contents
- Trials Overview
- Conditions and Patient Groups
- Trial Phases and Study Designs
- Main Endpoints and What They Mean
- Selected Trials by Research Question
- Who Might Qualify
- Patient-Friendly Terms
Trials Overview
The trial data show that Lutetium (177Lu) Oxodotreotide is being studied in many different cancer settings, especially neuroendocrine tumors and meningioma.[1][2][3] The studies include both early and later trial phases, and they are testing the treatment alone or with other medicines.[4][5]
Some trials compare the treatment with standard care, while others focus on dose, safety, radiation exposure, or how well the cancer responds.[6][7] The enrolled groups range from small pediatric studies to larger adult trials.[8]
Conditions and Patient Groups
Most trials focus on gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including advanced disease, well-differentiated tumors, and tumors with high proliferation rate.[9][10][11] Other trials study midgut neuroendocrine tumors, small intestinal neuroendocrine neoplasms, and neuroendocrine tumors in general.[12][13]
Some studies are designed for patients with meningioma, including recurrent or refractory cases, where local treatment options like surgery or radiotherapy are no longer available.[14][15] Other trials include children and adolescents with neuroblastoma, recurrent or relapsed solid tumors, or adolescent patients with GEP-NETs and pheochromocytoma/paragangliomas.[16][17][18]
One study also includes adults with extensive stage small cell lung cancer, showing that the research is not limited to one cancer type.[19]
Trial Phases and Study Designs
The research includes Phase 1, Phase 2, and Phase 3 trials.[20] Phase 1 studies are mainly about safety and dose finding, such as the pediatric neuroblastoma trial and the trial in children and adolescents with relapsed solid tumors.[21][22]
Phase 2 trials look at early signs of benefit and safety, including studies in adolescent patients, recurrent meningioma, and retreatment after progression in intestinal neuroendocrine tumor.[23][24][25]
Phase 3 trials compare the treatment with active comparator or standard care in larger groups, such as studies in advanced GEP-NET, neuroendocrine tumors, and the SAUNA trial.[26][27][28]
Some trials are randomized, meaning participants are assigned by chance to different study groups.[29] Some are open-label, which means both the study team and the participant know which treatment is being given.[30]
Main Endpoints and What They Mean
Many trials measure progression-free survival (PFS), which is the time before the cancer gets worse or the patient dies.[31][32] Other studies use relapse-free survival (RFS), which means the time before the cancer comes back after treatment.[33]
Several trials measure disease control rate (DCR), overall survival, response rate, or time to deterioration in symptoms or quality of life.[34][35][36] In some studies, the main outcome is safety, including adverse events, serious adverse events, laboratory toxicities, and dose-limiting toxicities.[37][38]
Some trials also measure absorbed radiation dose in target organs or tumors, which helps researchers understand how the treatment is distributed in the body.[39][40] Imaging tools such as PET-CT, MRI, and SPECT/CT are used in several studies to assess tumor changes or radiation uptake.[41][42]
Selected Trials by Research Question
Some trials ask whether adjuvant treatment can lower the risk of relapse after surgery or other initial treatment.[43] The phase 3 study in stage III small intestinal neuroendocrine neoplasms compares adjuvant treatment with close surveillance and measures relapse-free survival at 60 months.[43]
Other trials test whether retreatment or a different schedule can help patients with progressing disease. The phase 2 retreatment study in intestinal well-differentiated neuroendocrine tumor compares two additional cycles with active surveillance and measures disease control rate at 6 months.[44] The RIALTO study tests a less intensive schedule every 16 weeks in slowly progressive midgut neuroendocrine tumors and focuses on hematological toxicity, which means blood-related side effects.[45]
Several studies focus on meningioma. One randomized phase 2 trial in recurrent meningioma looks at progression-free survival, and another phase 2b study in grades 2 and 3 refractory meningioma tests whether adding everolimus improves PFS-6.[46][47]
Pediatric research includes a phase 2 study in children with relapsed or refractory high-risk neuroblastoma and a phase 1 study in children with recurrent or refractory neuroblastoma, both focused on response and dose or safety.[48][49] Another pediatric and adolescent study evaluates the treatment with olaparib in recurrent or relapsed solid tumors and looks at objective tumor response, safety, tolerability, and quality of life.[50]
One phase 1b/2 study in extensive stage small cell lung cancer combines the treatment with carboplatin, etoposide, and atezolizumab and measures dose-limiting toxicities and overall survival.[51]
Who Might Qualify
Eligibility depends on the trial, but most studies require a specific diagnosis and disease stage.[52] Many trials also require somatostatin receptor positive disease, which means the tumor has a feature that can be seen on certain scans and helps identify patients for these studies.[53]
Some studies are for adults only, while others are for adolescents or children.[54] A few studies also require that patients have no local treatment options left, or that their disease has already come back or progressed after earlier treatment.[55]
Patient-Friendly Terms
Randomization means a computer or chance decides which study group a person joins.[56] Active comparator means the new treatment is compared with another treatment already being used.[57]
Objective tumor response means the study team checks whether the tumor shrinks, stays stable, or grows on scans.[58] Quality of life means how the treatment affects daily life, symptoms, and overall well-being.[59]
Laboratory toxicities are changes in blood tests or other lab tests that may show the body is reacting to treatment.[60] Dose-limiting toxicities are side effects that are serious enough to limit how much treatment can be given.[61]
